VBC229 / VelaVigo - LARVOL DELTA

VBC229: A novel DLL3-targeting biparatopic T-cell engager-topoisomerase I inhibitor fusion molecule for depth and duration of response in small-cell lung cancer (AACR 2026) - "a proprietary linker, minimizing peripheral payload release while avoiding detectable cytotoxicity against PBMCs, thereby enhancing the safety profile.More importantly, in the preclinical studies, VBC229 demonstrated the superior therapeutic window comparing to Tarlatamab (Amgen's CD3×DLL3 TCE) - with greater antitumor activity but no excessive T-cell activation and CRS, especially with no detectable payload-induced cytotoxicity against PBMCs. Current development activities include CMC process optimization and dose-range-finding (DRF) toxicity studies, with an IND application scheduled for submission in H1 2027.In summary, VBC229 combines a differentiated antibody architecture and an innovative linker design, demonstrating promising preclinical efficacy and safety as a first-in-class candidate for SCLC clinical development."

Late-breaking abstract • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3